RTTNews | Jun 17, 2021 08:02AM EDT

08:01 Thursday, June 17, 2021 (RTTNews.com) - Synthetic biology firm Synlogic, Inc. (SYBX) announced Thursday that it has entered into a research collaboration agreement with Swiss drug major Roche Group (RHHBY) for the discovery of a novel Synthetic Biotic medicine for the treatment of inflammatory bowel disease (IBD).

Under the terms of the agreement, Synlogic and Roche will collaborate to develop a Synthetic Biotic medicine addressing an undisclosed novel target in IBD.

At the conclusion of the research period, Roche will have the exclusive option to enter a licensing and collaboration agreement for further development and commercialization of the program.

Read the original article on RTTNews ( https://www.rttnews.com/3203144/synlogic-partners-roche-to-develop-synthetic-biotic-medicine-for-inflammatory-bowel-disease.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved